New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
08:23 EDTRHHBYRoche acquisition makes sense, says Bernstein
Bernstein believes that Roche's (RHHBY) acquisition of InterMune (ITMN) makes sense strategically for Roche, as it "rounds out" the company's respiratory based offerings and it makes sense for the company to diversify, according to the firm. Although Bernstein believes that the price Roche is paying for InterMune will be viewed as high, the firm thinks that comes with the territory in the biotech space. It keeps an Outperform rating on Roche.
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 25, 2015
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
June 17, 2015
07:14 EDTRHHBYProthena announces PRX002 was safe, well tolerated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use